跳至主要内容
临床试验/NL-OMON35262
NL-OMON35262已完成2 期

The effect of vitamin K2 supplementation on cardiovascular risk markers. - Vitamin K2 and CVD risk markers.

niversitair Medisch Centrum Utrecht0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • -Men and women aged >= 40 and <= 65 years at Day 01 of the study
  • -Postmenopausal assessed by self-reported absence of menstrual periods for at least 1 year
  • -Body mass index (BMI) >= 18.5 and <= 30

排除标准

  • -Using vitamin K antagonists
  • -Using chronic medication for cardiovascular diseases (beta blockers, bloodthinner medication, rate control medication, cholesterol lowering medication, diuretics, vasodilators)
  • -For women: using menopausal hormone therapy
  • -having a known history with coagulation problems
  • -Using vitamin supplements that contain vitamin K, vitamin D or calcium
  • -A high vitamin K2 intake (>= 90 µg/day)
  • -Consuming natto
  • -Soy allergy

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验